Innovent Biologics (1801.HK) hit highest since Jan on 40% product revenue growth in 2024, potential Hang Seng Index inclusion
Innovent Biologics (1801.HK) hit highest since Jan on 40% product revenue growth in 2024, potential Hang Seng Index inclusion